Iterum TherapeuticsITRMF +18.86% FCF Yield % is -653.11 as of Jun. 25, 2026. The stock has 4 warning signs investors should review. Among 1,418 Biotechnology companies, Iterum Therapeutics ranks worse than 98.8% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Iterum Therapeutics FCF Yield % Related Terms
Iterum Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Iterum Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Iterum Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics (ITRMF) has a FCF Yield % of -653.11 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #1401 out of 1418 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Iterum Therapeutics' FCF Yield % too high?
Iterum Therapeutics' current FCF Yield % is -653.11. Based on the distribution chart, Iterum Therapeutics ranks #1401 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Iterum Therapeutics' FCF Yield % compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #1401 out of 1418 companies for FCF Yield %. This places Iterum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current FCF Yield % is -653.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current FCF Yield % of -653.11. The current FCF Yield % is -653.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current FCF Yield % is -653.11 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITRMF has been successfully added to your 